Charles River Laboratories International, Inc. (CRL) is a pre-eminent global contract research organization (CRO) providing a large range of products and services to the pharmaceutical, biotechnology, and medical device industries. This corporation was founded in 1947 and is based in Wilmington, Massachusetts, USA. It is dedicated to aiding its partners with early-stage drug discovery, preclinical development, and support for clinical trials.
Dedicated and committed to its mission, Charles River Laboratories works tirelessly to accelerate the development of new therapies, making groundbreaking contributions to the healthcare industry. The company's comprehensive range of services includes laboratory animal research models, drug discovery and development, safety assessment, biologics testing, and manufacturing support. With a strong focus on service, quality, and collaboration, CRL is a highly respected partner for companies at every stage of the drug development process.
The company has a global presence with 100 facilities spanning 20 countries in North America, Europe, Asia, and the Pacific region. This international reach allows CRL to provide its partners with integrated research solutions and support, wherever their research may be based.
The foundational strength of Charles River Laboratories is its dedicated team of scientists and support staff, whose innovative approach and commitment to quality ensures they consistently meet their client's expectations. Moreover, the company follows an ethical approach, guaranteeing the welfare and humane care of its laboratory animals and strictly adheres to compliance with animal welfare regulations.
Charles River Laboratories plays a unique role by providing the pivotal services and necessary expertise that enable its clients to bring new therapeutics to market. The company has continuously demonstrated a successful track record, and their significant contributions to the approval of drugs is a clear indication of their impact in the field.
In essence, Charles River Laboratories, Inc. is more than just a company, it is a strategic partner that provides customized and comprehensive solutions to empower researchers and drive medical advances. The company stands as a testament to the essential role of contract research organizations in paving the way towards better healthcare and therapeutic solutions.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
City Therapeutics, an RNAi biotech co-founded by Alnylam founder Maraganore, has filed for an initial public offering (IPO) on Nasdaq under the ticker CTY. The company, which has raised approximately $238.8 million since its launch in October 2024, currently employs 81 people and has established partnerships with Bausch + Lomb and Biogen. The IPO aims to build on the success of Alnylam Pharmaceuticals Inc.
Celldex Therapeutics, Inc. (CLDX) is drawing market attention after its barzolvolimab studies in chronic spontaneous urticaria met primary and key secondary endpoints. This development highlights the company's operating priorities and its position within the Healthcare Stocks sector. Investors are now focused on consistent execution and how these positive clinical results translate into sustained operational success and customer response.
Coca-Cola's consistent dividend growth for over 60 years is attributed to its asset-light business model, primarily selling concentrate and syrup to bottlers, which results in high gross margins and strong free cash flow. This model allows KO to comfortably cover its substantial dividend payments, unlike peers PepsiCo and Keurig Dr Pepper who have heavier reinvestment burdens. While the free cash flow coverage is robust, investors should monitor the company's relatively high earnings-based payout ratio and projected EPS growth for future dividend sustainability.
RBC has increased its price target for Charles River Laboratories International (CRL) to $322 from $282, while maintaining an "Outperform" rating on the stock. This adjustment reflects a positive outlook from the analyst firm on the biotechnology and medical research company. The article also notes other recent analyst actions, mostly showing increased price targets for CRL.
Evercore ISI has increased its price target for Charles River Laboratories International (CRL) to $330 from $320, while reaffirming an Outperform rating on the stock. This adjustment reflects a positive outlook from the analyst firm on the biotechnology and medical research company. The news comes alongside several other analyst adjustments for Charles River Laboratories, indicating active re-evaluation by financial institutions.
Barclays has increased its price target for Charles River Laboratories International (CRL) to $330 from $300, while maintaining an "Overweight" rating on the stock. This adjustment reflects a positive outlook from the analyst firm for the biotechnology and medical research company. The news comes alongside similar price target adjustments from other analysts like Mizuho, TD Cowen, and Baird, indicating broader analyst confidence in CRL's performance.